Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors.

Rudin CM, Pandha HS, Zibelman M, Akerley WL, Harrington KJ, Day D, Hill AG, O'Day SJ, Clay TD, Wright GM, Jennens RR, Gerber DE, Rosenberg JE, Ralph C, Campbell DC, Curti BD, Merchan JR, Ren Y, Schmidt EV, Guttman L, Gupta S

Open source

DOI: 10.1136/jitc-2022-005007
Published: 2023 Jan
Container: Journal for immunotherapy of cancer
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1136/jitc-2022-005007,
  title = {Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors.},
  author = {Rudin CM and Pandha HS and Zibelman M and Akerley WL and Harrington KJ and Day D and Hill AG and O'Day SJ and Clay TD and Wright GM and Jennens RR and Gerber DE and Rosenberg JE and Ralph C and Campbell DC and Curti BD and Merchan JR and Ren Y and Schmidt EV and Guttman L and Gupta S},
  year = {2023},
  journal = {Journal for immunotherapy of cancer},
  doi = {10.1136/jitc-2022-005007},
  url = {https://doi.org/10.1136/jitc-2022-005007}
}

RIS

TY  - JOUR
TI  - Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors.
AU  - Rudin CM
AU  - Pandha HS
AU  - Zibelman M
AU  - Akerley WL
AU  - Harrington KJ
AU  - Day D
AU  - Hill AG
AU  - O'Day SJ
AU  - Clay TD
AU  - Wright GM
AU  - Jennens RR
AU  - Gerber DE
AU  - Rosenberg JE
AU  - Ralph C
AU  - Campbell DC
AU  - Curti BD
AU  - Merchan JR
AU  - Ren Y
AU  - Schmidt EV
AU  - Guttman L
AU  - Gupta S
PY  - 2023
JO  - Journal for immunotherapy of cancer
DO  - 10.1136/jitc-2022-005007
UR  - https://doi.org/10.1136/jitc-2022-005007
ER  -

APA

CM, R., HS, P., M, Z., WL, A., KJ, H., D, D., AG, H., SJ, O., TD, C., GM, W., RR, J., DE, G., JE, R., C, R., DC, C., BD, C., JR, M., Y, R., EV, S., L, G., & S, G. (2023). Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors.. Journal for immunotherapy of cancer. https://doi.org/10.1136/jitc-2022-005007

Source records

pubmed · retrieved 2026-09-25T19:58:30.927Z
europe-pmc · retrieved 2026-09-25T19:58:30.952Z
doaj · retrieved 2026-09-25T19:58:30.946Z